Table 1.
Cohort demographic characteristics
| Characteristic | Nonpregnant (n=16), n (%) | Pregnant (n=84), n (%) | Lactating (n=31), n (%) |
|---|---|---|---|
| Participant age, mean (SD), y | 38.4 (8.3) | 34.1 (3.3) | 34.6 (2.6) |
| Race | |||
| White | 12 (75) | 75 (89) | 27 (87) |
| Black | 2 (12) | 2 (2) | 0 (0) |
| Asian | 0 (0) | 6 (7) | 2 (6) |
| Multiracial | 0 (0) | 1 (1) | 1 (3) |
| Other | 1 (6) | 0 (0) | 1 (3) |
| Unknown | 1 (6) | 0 (0) | 0 (0) |
| Ethnicity | |||
| Hispanic or Latino | 0 (0) | 5 (6) | 2 (6) |
| Not Hispanic or Latino | 14 (88) | 79 (94) | 28 (90) |
| Unknown or not reported | 2 (12) | 0 (0) | 1 (3) |
| Maternal comorbidities | |||
| Chronic hypertension | 1 (6) | 3 (4) | 3 (10) |
| Diabetes mellitus or gestational diabetes | 0 (0) | 3 (4) | 3 (10) |
| BMI of >30 kg/m2 | 2 (12) | 10 (12) | 3 (10) |
| Asthma | 2 (12) | 16 (19) | 7 (23) |
| Immunosuppression/cancer | 0 (0) | 3 (4) | 0 (0) |
| Previous SARS-CoV-2 infection | 1 (6) | 2 (2) | 2 (6) |
| Vaccine type | |||
| Pfizer-BioNTech | 8 (50) | 41 (49) | 16 (52) |
| Moderna | 8 (50) | 43 (51) | 15 (48) |
| Gestational age at first vaccine dose | n/a | 23.2 (16.3–32.1) | n/a |
| Trimester of first vaccine dose | n/a | n/a | |
| - First | 11 (13) | ||
| - Second | 39 (46) | ||
| - Third | 34 (40) | ||
| Time points for blood collection | |||
| - Baseline/at first dose (V0) | 1 (6) | 31 (37) | 14 (45) |
| - At second dose (V1) | 15 (94) | 78 (93) | 26 (84) |
| - 2–5.5 wk after second dose (V2) | 16 (100) | 17 (20) | 13 (42) |
| Time points for milk collection | |||
| - Baseline or at first dose (V0) | — | 3 (4) | 16 (52) |
| - At second dose (V1) | — | 26 (31) | 28 (90) |
| - 2–5.5 wk after second dose (V2) | — | 0 (0) | 13 (42) |
| Side effects at first vaccine dosea | |||
| - Injection site soreness | 12 (75) | 73 (88) | 20 (67) |
| - Injection site reaction or rash | 0 (0) | 1 (1) | 0 (0) |
| - Headache | 5 (31) | 7 (8) | 9 (30) |
| - Muscle aches | 2 (12) | 2 (2) | 4 (13) |
| - Fatigue | 6 (38) | 12 (14) | 4 (13) |
| - Fever or chills | 1 (6) | 1 (1) | 1 (3) |
| - Allergic reaction | 0 (0) | 0 (0) | 0 (0) |
| - Otherb | 2 (6) | 3 (4) | 0 (0) |
| Side effects at second vaccine dosec | |||
| - Injection site soreness | 12 (75) | 44 (57) | 17 (61) |
| - Injection site reaction or rash | 0 (0) | 1 (1) | 0 (0) |
| - Headache | 6 (38) | 25 (32) | 11 (39) |
| - Muscle aches | 7 (44) | 37 (48) | 16 (57) |
| - Fatigue | 9 (56) | 41 (53) | 14 (50) |
| - Fever or chills | 8 (50) | 25 (32) | 12 (43) |
| - Allergic reaction | 0 (0) | 1 (1) | 0 (0) |
| - Otherd | 2 (12) | 7 (9) | 7 (25) |
BMI, body mass index; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SD, standard deviation.
Gray et al. Coronavirus disease 2019 vaccination in pregnancy and lactation. Am J Obstet Gynecol 2021.
Not all participants provided side effect data after the first dose: 2 patients (1 pregnant, 1 lactating) did not provide information. Thus, percentages are based off of 16 nonpregnant, 79 pregnant, and 30 lactating participants
“Other” side effects reported after vaccine dose 1: elevated heart rate, joint pain, nausea, swollen lymph node, or sore throat
Not all participants received the second dose at the time of analysis: 16 nonpregnant, 80 pregnant, and 29 lactating patients received the second dose. Of those who received the second dose, 4 did not provide side effect data (3 pregnant, 1 lactating). Thus, percentages are based off of 16 nonpregnant, 77 pregnant, and 28 lactating participants
“Other” side effects reported after the vaccine dose 2: joint pain, nausea, sore throat, dizziness/light headedness, stomach ache, night sweats, clogged ears, or swollen eyes.